Car T-Cell Therapy Market size is set to grow by USD 3.02 billion from 2024-2028, Growing awareness regarding car T-cell therapy to boost the market growth, Technavio [Yahoo! Finance]
Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
The market is estimated to grow at a CAGR of 16.83% during the forecast period. Growing awareness regarding car t-cell therapy is driving market growth, with a trend towards rising number of product approvals and clinical trials related to car T- cell therapy. However, high cost associated with car t-cell therapy poses a challenge. Key market players include ACROBIOSYSTEMS INC., Allogene Therapeutics Inc., Autolus Therapeutics plc, Bristol Myers Squibb Co., Celyad Oncology SA, Eli Lilly and Co., Fate Therapeutics Inc., Fortress Biotech Inc., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Les Laboratoires Servier, Merck KGaA, Miltenyi Biotec B.V. And Co. KG, Noile Immune Biotech Inc., Novartis AG, Pfizer Inc., Sangamo Therapeutics Inc, Sorrento Therapeutics Inc., and TCR2 Therapeutics Inc.. Get a detailed analysis on regions, market segments, customer landscape, and companies - Click for the snapshot of this report Forecast period Base Year Histor
Show less
Read more
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- Allogene Therapeutics Announces Participation in February Investor ConferencesGlobeNewswire
- Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical OfficerGlobeNewswire
- Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune DiseasesGlobeNewswire
- Foresight Diagnostics Provides 2025 Outlook and 2024 Year in Review [Yahoo! Finance]Yahoo! Finance
- 3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying [Yahoo! Finance]Yahoo! Finance
ALLO
Earnings
- 11/7/24 - Beat
ALLO
Sec Filings
- 2/5/25 - Form 4
- 2/5/25 - Form 4
- 2/5/25 - Form 4
- ALLO's page on the SEC website